Pharmaceuticals, Biotechnology and Life Sciences
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial.
ViGeneron GmbH, a next-generation gene therapy company, has announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
Coalition ignites strategic insights sooner to accelerate patient access BASKING RIDGE, N.J. & MORRISVILLE, N.C.–(BUSINESS WIRE)–Daiichi Sankyo, Inc. (hereafter, Daiichi…
First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) GIST…
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Daiichi Sankyo and AstraZeneca’s Enhertu trastuzumab has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.
Exelixiswill receive an associated $20 million milestone payment from DaiichiSankyo under the terms of the companies’ collaboration agreement.